PHARMACEUTICAL 2026

Abbott Laboratories
Rank 14 of 178



PHARMACEUTICAL 2026

Abbott Laboratories
Rank 14 of 178

The relative strengths and weaknesses of Abbott Laboratories are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Abbott Laboratories compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 89% points.The greatest weakness of Abbott Laboratories is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 376%, being 147% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	25,996,000
Cost of Goods Sold	19,319,000
Intangible Assets	29,561,000
Liabilities, Current	16,496,000
Liabilities, Non-Current	0
Other Assets	19,340,000
Other Compr. Net Income	1,905,000
Other Expenses	4,117,000
Other Liabilities	0
Other Net Income	906,000
Other Revenues	44,328,000
Property and Equipment	11,816,000
Research and Development	2,942,000
Selling, General and Administrative Expense	12,332,000

Output Variable	Value in 1000 USD
Assets	86,713,000
Liabilities	16,496,000
Expenses	38,710,000
Revenues	44,328,000
Stockholders Equity	70,217,000
Net Income	6,524,000
Comprehensive Net Income	7,476,500
BaseVar	94,529,000
ECR before LimitedLiability	311%
Economic Capital Ratio	376%